Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/13787
Title: | Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection | Authors: | Mackiewicz, Andrzej Mackiewicz, Jacek Wysocki, Piotr J. Wiznerowicz, Maciej Kapcinska, Malgorzata Laciak, Maria Rose-John, Stefan Izycki, Dariusz BURZYKOWSKI, Tomasz Karczewska-Dzionk, Aldona |
Issue Date: | 2012 | Publisher: | INFORMA HEALTHCARE | Source: | EXPERT OPINION ON INVESTIGATIONAL DRUGS, 21 (6), p. 773-783 | Abstract: | Objective: Two single arm, Phase II trials (3 and 5) were undertaken to determine the efficacy and toxicity of an adjuvant treatment using Hyper-IL-6 gene-modified whole-cell allogeneic melanoma vaccine in patients with stage IIIB-IV resected disease. Research design and methods: Ninety-seven and 99 patients were enrolled into Trials 3 and 5, respectively. The primary endpoint was disease-free survival (DFS), and the secondary was overall survival (OS). Vaccine was administered eight times every 2 weeks (induction), every month (maintenance) until patient's death. At progression, maintenance was continued or induction was repeated followed by maintenance. Results: Median follow-up was 10.5 and 6.2 years for Trials 3 and 5, respectively. No grade 3 or 4 toxicities were observed. An extension of DFS and OS was observed, when compared with historical non-treated controls. DFS probability at 5 years for Trials 3 and 5 was, respectively, 54.8% and 40.6% for stage IIIB, 25.0% and 24.0% for IIIC, and 8.5% and 17.7% for IV. OS probability at 5 years was, respectively, 66.7% and 56.3% for IIIB, 43.8% and 39.8% for IIIC, and 26.1% and 41.2% for IV. Conclusions: Continuous vaccination, regardless of the disease progression, re-induction, and immunization of patients until death resulted in patients a long-term survival. | Notes: | [Mackiewicz, Andrzej; Wysocki, Piotr J.; Wiznerowicz, Maciej; Kapcinska, Malgorzata; Laciak, Maria; Rose-John, Stefan; Burzykowski, Tomasz] Poznan Univ Med Sci, Chair Med Biotechnol, Poznan, Poland. [Mackiewicz, Andrzej; Mackiewicz, Jacek; Kapcinska, Malgorzata] Greater Poland Canc Ctr, Dept Canc Diagnost & Immunol, Poznan, Poland. [Mackiewicz, Andrzej; Laciak, Maria; Rose-John, Stefan] BioContract Sp Zoo, Poznan, Poland. [Wiznerowicz, Maciej] Greater Poland Canc Ctr, Dept Chemotherapy, Poznan, Poland. [Izycki, Dariusz] Inst Biochem, D-24098 Kiel, Germany. [Izycki, Dariusz] Univ Kiel, Kiel, Germany. [Karczewska-Dzionk, Aldona] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. | Keywords: | Pharmacology & Pharmacy, advanced melanoma; genetic melanoma vaccine; long-term survivals; Phase II clinical trials; re-induction;advanced melanoma; genetic melanoma vaccine; long-term survivals; Phase II clinical trials; re-induction | Document URI: | http://hdl.handle.net/1942/13787 | ISSN: | 1354-3784 | e-ISSN: | 1744-7658 | DOI: | 10.1517/13543784.2012.684753 | ISI #: | 000304063400003 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2013 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
18
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
27
checked on Sep 27, 2024
Page view(s)
72
checked on Apr 17, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.